Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
doi: https://doi.org/10.1101/2022.03.03.22271827
Masaharu Shinkai
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Takuhiro Sonoyama
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Akari Kamitani
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Risa Shibata
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Naomi Seki
3Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
Shinya Omoto
3Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan
Masahiro Shinoda
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Takashi Sato
1Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Naoki Ishii
4Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi, Shinagawa-ku, Tokyo 140-8522, Japan
Kenji Igarashi
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan
Mari Ariyasu
2Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan

- Supplementary Appendix[supplements/271827_file06.docx]
Posted April 01, 2022.
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
medRxiv 2022.03.03.22271827; doi: https://doi.org/10.1101/2022.03.03.22271827
Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study
Masaharu Shinkai, Takuhiro Sonoyama, Akari Kamitani, Risa Shibata, Naomi Seki, Shinya Omoto, Masahiro Shinoda, Takashi Sato, Naoki Ishii, Kenji Igarashi, Mari Ariyasu
medRxiv 2022.03.03.22271827; doi: https://doi.org/10.1101/2022.03.03.22271827
Subject Area
Subject Areas
- Addiction Medicine (425)
- Allergy and Immunology (746)
- Anesthesia (219)
- Cardiovascular Medicine (3246)
- Dermatology (271)
- Emergency Medicine (476)
- Epidemiology (13272)
- Forensic Medicine (19)
- Gastroenterology (893)
- Genetic and Genomic Medicine (5082)
- Geriatric Medicine (473)
- Health Economics (778)
- Health Informatics (3208)
- Health Policy (1131)
- Hematology (424)
- HIV/AIDS (1006)
- Medical Education (469)
- Medical Ethics (126)
- Nephrology (518)
- Neurology (4843)
- Nursing (257)
- Nutrition (718)
- Oncology (2492)
- Ophthalmology (710)
- Orthopedics (280)
- Otolaryngology (341)
- Pain Medicine (321)
- Palliative Medicine (89)
- Pathology (533)
- Pediatrics (1287)
- Primary Care Research (552)
- Public and Global Health (7414)
- Radiology and Imaging (1681)
- Respiratory Medicine (976)
- Rheumatology (474)
- Sports Medicine (417)
- Surgery (537)
- Toxicology (71)
- Transplantation (234)
- Urology (202)